Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Trial details
- Registry ID
- NCT05678673
- Phase
- Phase 3
The FDA approved Nivolumab (BMS-936558) on 22 Dec 2014.
Drug identity checked against registry records
Also recorded as BMS-936558; OPDIVO; Opdivo; Opdivo®
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-12-22Day | Nivolumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125554", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["OPDIVO"], "active_ingredients": ["NIVOLUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20141222", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |